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Peptide constructs were engineered by colinear synthesis of two short synthetic peptide deter- 
minants: a determinant recognized by T helper cells (TD,) and a determinant recognized by T 
cytotoxic cells (TD,). Three types of constructs were synthesized: TD,-TDr, , TD,-TD, , and TD,,- 
KK-TD,, where KK are two lysine residues. In vivo immunization with free construct induced 
cytolytic lymphocytes (CTL) only in the case of TD,-TD,,. However, immunization with spleen 
cells to which these constructs had been internalized by hypertonic shock, induced CTL activity 
in all three cases. No CTL could be induced after immunization with free TD, in either protocol. 
These results indicate that cell internalization of the construct might be essential for CTL induction, 
and also, that “help” from the TDr, seems to be required. o 1992 Academic PKSS, IX. 
INTRODUCTION 
It is well established that two main types of immune responses are elicited after 
challenge with complex antigens; (i) the humoral, which leads to antibody production; 
and (ii) the cellular, which leads to the induction and proliferation of cytotoxic T 
lymphocytes (CTL). 
Our understanding of how T-cell help is provided to antibody producing B-cells 
has greatly benefited from immunization studies using peptide haptens linked to a 
peptide determinant sequence (TDJ2 recognized by T-cells ( 1-6) as well as by im- 
munization with mixtures of hapten and TD,, molecules injected in the same im- 
munization site (7). 
The cellular immune response has been studied using recombinant viral protein 
preparations (S- 10) as well as peptides (1 l- 17). Three different ypes of peptide prep- 
arations have been reported as being able to induce CTL in vivo. Carbone and Bevan 
(11) and Ishioka et al. (12) used trypsin-digested chicken ovalbumin fragments in 
C57BL/6 mice. Deres et al. ( 13) immunized BALB/c mice with a synthetic lipopeptide 
construct consisting of tripalmitoil-S-glycerylcysteinyl-seryl-serine bound to a viral 
’ To whom correspondence should be addressed. 
* Abbreviations used: TD,,, determinant recognized by helper T cells; TD,, determinant recognized by 
cytotoxic T cells. 
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cytolytic T-cell determinant peptide (TD,). More recently, Schild et al. ( 14) found 
that the lipophilic moiety of lipopeptide construct of Deres et al. (13) was essential 
for an efficient in vivo priming of CTL. Aichele et al. (15) induced CTL in BALB/c 
mice after priming with a free 15-mer synthetic peptide encompassing a sequence of 
lymphocytic choriomeningitis virus nucleoprotein and Schulz et al. (16) found that 
this peptide was protective. Kast et al. ( 17) were able to induce protective CTL against 
Sendai virus after immunization of mice with a free 16-mer peptide from the nucleo- 
protein of the virus. 
Based on the observations that the tripalmitoil-S-glycerylcysteinyl-seryl-serine moiety 
used in the construct of Deres et al. ( 13) behaves as a TD,, in another type of construct 
(18) and the ovalbumin tryptic fragment 229-276, which contains a predicted TDi, 
according to Sette’s algorithm ( 19) and a proven TD, (20) but not the 242-276 (which 
only contains the TD,) is able to induce CTL in vivo (1 I), we speculated that synthetic 
colinear peptide constructs of the type TDh-TD, or TD,-TDh might be able to induce 
CTL in vivo. Ishioka et al. (12) have suggested a similar proposition; however, to our 
knowledge, no experimental evidence has yet been published to validate these hy- 
pothesis. 
We show below that CTL induction in vivo depends on the type of peptide 
construct used. 
MATERIALS AND METHODS 
Peptide Synthesis 
Peptides were synthesized by the solid phase method of Merrifield (21) using the 
Fmoc alternative (22). The synthesis was done manually and the ninhydrin test of 
Kaiser (23) was used to monitor every step. Couplings were repeated if necessary until 
a negative ninhydrin test was attained. All peptides were purified by HPLC on a 
reverse-phase C 18 column. 
Internalization of Peptides in Cells 
Peptides were internalized in the cytoplasm of homogenized spleen cells from 
BALB/c mice by osmotic lysis of pinosomes induced by hypertonic shock as described 
(20, 24) using 300 pg/ml of peptide. 
Induction of CTL 
Groups of three 6-week-old female BALB/c mice were primed by ip injection of 
100 pg of relevant peptide dissolved in 0.5 ml of RPM1 1640 solution at Days 1, 8, 
and 15. Alternatively, mice were immunized ip with a single dose of syngenic spleen 
cells (5 X lo6 cells in 0.5 ml of RPM1 1640) having been submitted to hypertonic 
treatment in the presence of peptide. A week after the third injection of peptide or 3 
weeks after immunization with cells, the animals were killed and their spleens were 
removed. Spleen cells were restimulated with 5 pg/ml of the relevant peptide according 
to Ishioka et al. (12). Cytolytic activity was measured 5 days after initial culture and 
after establishing CTL lines by repeated restimulations. 
Cytotoxicity Assay 
CTL activity was measured using the conventional cytotoxicity assay (12). Target 
cells P8 15 (H-2d-restricted) or EL-4 (H-2b-restricted) previously incubated with 5 pg/ 
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ml of relevant peptide were used. The assays were done in triplicate; the spontaneous 
release was in all cases below 20% of total release. 
Immunization Experiments for Antibody Induction 
BALB/c mice were immunized by ip injection as previously described (6). 
Assessment of the Topography of Peptides with Antibodies 
The degree of “surface xposure” of regions from the peptide constructs was assessed 
by ELISA (6) using specific anti-peptide antibodies for each region. For the competition 
experiments, the antibodies were incubated with free competitor peptide in solution 
for 1 hr at 37°C before adding this mixture to the ELISA well containing the peptide 
adsorbed on the plastic. 
RESULTS 
To test if constructs of the type TD,-TDh or TD,-TD, could induce CTL in 
vivo we synthesized KQIINMWQEVGKAMYA (from now on KQI) and 
RIQRGPGRAFVTIGK (RIQ), encompassed respectively by amino acids 428-443 
and 3 15-329 from HIV-l-IIIB gp120 (positions according to Ratner et al. (25)). We 
also synthesized the constructs RIQRGPGRAFVTIGKKQIINMWQEVGKAMYA 
(RIQ-KQI) and KQIINMWQEVGKAMYARIQRGPGRAFVTIGK (KQI-RIQ) 
representing the two possible N-terminal to C-terminal permutations (TD,-TD,, or 
RIQ-KQI and TD,-TD, or KQI-RIQ) of the above peptides. KQI and RIQ have 
been reported as TD,, and TD, in BALB/c mice, respectively (9, 26). 
Induction of CTL by Immunization with Free Peptides 
To attempt CTL induction in vivo, five groups of BALB/c mice were immunized 
with peptides RIQ, KQI, RIQ-KQI, KQI-RIQ, and a mixture of KQI and RIQ, 
respectively. The spleen cells of each group of mice were isolated and cultured in vitro 
for 5 days under stimulation with different combinations of the above peptides. T’hese 
cell cultures were next assayed for cytolytic activity against radioactively labeled target 
cells previously incubated with different peptides. 
Figure 1 shows that specific cytolitic activity could be induced by in vivo priming 
with peptide RIQ-KQI (panels a and b) but not with free RIQ or with KQI-RIQ 
(panels d and e), respectively. Immunization with a mixture of RIQ and KQI gave 
lower, but significant levels of CTL. No CTL could be induced with free KQI (data 
not shown). 
A peptide KQI-KK-RIQ, having two potential cleavage sites at the frontier between 
KQI and RIQ (the two lysines in bold), was synthesized and tested. This peptide was 
unable to induce CTL in vivo (data not shown), a result that was confirmed in another 
group of experiments (Table 2). 
Mapping the Surface of Peptides with Antibodies 
The degree of “surface exposure” of KQI and RIQ in the above peptide constructs 
was tested by ELISA with anti-RIQ- and anti-KQI-specific antibodies (induced by 
immunization with free RIQ and KQI, respectively). Table 1 shows that the KQI 
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FIG. 1. CTL activity of spleen cells of BALB/c mice after in viva immunization and in vitro restimulation 
with the peptides hown on top of each panel. Activity is expressed as the percentage of specific lysis of P8 15 
target cells preincubated with peptides (El) RIQ-KQI, (0) KQI-RIQ, (+) RIQ, (B) KQI, (X) irrelevant 
control peptide. This lysis was induced by effector cells at the effector-to-target ratios (E:T) shown. The 
irrelevant control peptide corresponds to FERFEIFP, which encompasses amino acids 11 I- I 18 of influenza 
virus hemagglutinin. 
moiety is well recognized by anti-KQI antibodies in construct RIQ-KQI but not in 
KQI-RIQ or KQI-KK-RIQ. By contrast, the RIQ moiety is well recognized by anti- 
RIQ antibodies in KQI-RIQ, KQI-KK-RIQ but not in RIQ-KQI. Qualitatively 
equivalent results were obtained in inhibition experiments using these peptide con- 
structs to neutralize the recognition of RIQ and KQI (adsorbed on the ELISA plate) 
by anti-RIQ and anti-KQI antibodies (data not shown). 
INDUCTION OF CYTOTOXIC T LYMPHOCYTES 215 
TABLE I 
Recognition Antibody Titers” (X IO-‘) of RIQ and KQI in Three Different Peptide Constructs 
by Antisera Specific for Each of These Moieties 
Recognition by anti-KQI 
Peptide construct antibodies 
RIQ-KQI 10 
KQI-RIQ 0.8 
KQI-KK-RIQ 2 
’ The titers shown are the mean from three different mice. 
Recognition by anti-RIQ 
antibodies 
0.9 
13 
13 
Induction of CTL with Peptide-Containing Cells as Compared to Immunization with 
Free Peptides 
To study the effect of peptide internalization in the cell on CTL induction in vivo, 
mice were immunized with one of the following peptides: RIQ, RIQ-KQI, KQI-RIQ, 
KQI-KK-RIQ, and a mixture of KQI and RIQ or with syngenic spleen cells subjected 
to peptide internalization. 
In Table 2 we summarize the results obtained with both types of immunizations. 
In the group immunized with free peptides, specific cytolitic activity could be induced 
by in vivo priming with a peptide construct consisting of a colinear combination of a 
TD,-TDi, (RIQ-KQI) amino acid sequences, and to a lower extent after in vivo priming 
with a mixture of RIQ and KQI, thus confirming the results of immunization exper- 
iments shown in Fig. 1. No induction was achieved by priming with KQI-RIQ (as in 
Fig. 1) or with KQI-KK-RIQ. By contrast, immunization with spleen cells containing 
RIQ-KQI, KQI-RIQ, or KQI-KK-RIQ could all induce CTL in vivo whereas im- 
munization with spleen cells containing a mixture of RIQ and KQI gave a marginal 
response. No response could be induced after immunization with free RIQ or with 
RIQ-containing cells. No significant response was obtained after in vivo immunization 
with RPM1 alone, or with spleen cells subjected to hypertonic shock in the absence 
of peptide, and in vitro restimulation with peptides. 
TABLE 2 
Percentage of Specific Lysis Induced after Immunization with Free Peptide 
or with Peptide-Containing Syngenic Cells 
Peptide tested 
Induced with free Induced with peptide- 
peptide containing cells 
RIQ-KQI 31 28 
KQI-RIQ 13.5 22 
KQI + RIQ 18 14 
RIQ 13.2 11 
KQI-KK-RIQ 6 30 
None 7 10 
Note. Results were obtained after a single in vitro restimulation with free RIQ and testing CTL activity 
using P8 15 cells incubated with RIQ. The effector-to-target ratio was 30: I in both experiments. 
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Surface Phenotype and Class I MHC Restriction of Induced CTL 
To characterize the lymphocytes induced after in vivo priming with RIQ-KQI, 
these lymphocytes were treated with fluorescently labeled anti-CD4 and anti-CD8 
antibodies and analyzed by flow cytometry. This showed that around 95% of them 
were conventional CD8+ CD4-. Moreover, only P8 15 target cells (H-2d-restricted) but 
not EL-4 cells (H-2b-restricted), incubated with RIQ, were lysed by these lymphocytes 
(data not shown). Since these target cells are Ia-, it can be concluded that the induced 
CTL are H-2d class I-restricted. 
DISCUSSION 
CTL Induction with Peptides, Efect of Epitopes within Constructs 
Figures la and lb show that specific cytolitic activity can be induced by in vivo 
priming with a peptide construct consisting of a colinear combination of a TD,-TD,, 
(RIQ-KQI) amino acid sequence. This induction cannot be obtained in the absence 
of KQI, that is, induction of CTL requires help from KQI (compare Fig. la with Fig. 
Id). The in vitro restimulation does not require KQI since similar percentages of 
specific lysis can be obtained with and without KQI in the medium (compare Fig. la 
with Fig. lb). However, as expected, the presence of RIQ during restimulation is 
essential for cytolitic activity because if only KQI is used no lysis is observed (data 
not shown). 
An interesting aspect of this work is the finding that although CTL priming in vivo 
is efficiently attained with RIQ-KQI, restimulation in vitro prefers free RIQ over RIQ- 
KQI (compare Figs. la and lb with lc). Moreover, the relative position of RIQ and 
KQI has a dramatic effect on CTL induction in vivo. Thus, RIQ-KQI is active as 
judged by the percentages of specific lysis induced after in vitro restimulation with 
either RIQ alone or with a mixture of RIQ and KQI (see Figs. la and 1 b) whereas 
KQI-RIQ does not show any sign of activity after in vitro restimulation with RIQ 
(compare Fig. la with Fig. le). These results suggested to us that enzymatic processing 
to free active RIQ might be more favorable in RIQ-KQI than in KQI-RIQ, a similar 
result to the one found for TDh-hapten peptide constructs concerning the induction 
of anti-hapten antibodies (6). It is interesting to note that in the sequence 
RIQRGPGRAFVTIGKKQIINMWQEVGKAMYA (construct RIQ-KQI) two resi- 
dues of K (in bold) are side by side in positions 15 and 16. These residues might 
define a more accessible trypsin-like cleavage site to generate free RIQ, a situation 
which would not be as favorable in peptide KQIINMWQEVGKAMY- 
ARIQRGPGRAFVTIGK. Thus, active TD,-TDr, or TD,-TD, peptide constructs 
might need to have a “cleavable” site between the TD, and TDr, sequences. The 
understanding of how these constructs are processed would greatly facilitate the en- 
gineering of tailor-made constructs for a given individual, that is, of how to use TD, 
and TD,, sequences recognized by class I and class II MHC molecules of this individual. 
Irrespective of interpretation, the experimental results discussed above, stress the im- 
portance of choosing the most adequate position of both TD, and TD,, to generate 
active peptide constructs. 
Another aspect concerning the induction of CTL in vivo is whether the TD, and 
TD,, need to be covalently linked to induce CTL, or perhaps it might suffice to prime 
with a mixture of them, a result that might resemble the induction of antibodies using 
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another type of peptide constructs (7). Comparison of Figs. la and lb with Fig. If 
show that CTL induction is clearly more efficient after priming with RIQ-KQI than 
after priming with a mixture of RIQ and KQI. In this last case, lower but significant 
CTL induction seems to have taken place. 
Since efficient processing of the constructs inside the cell, to liberate the TD, (RIQ 
in the above constructs), might be important for the induction of CTL, we synthesized 
the peptide KQI-KK-RIQ, having two added potentially cleavable sites at the frontier 
between KQI and RIQ (the two lysines in bold) to attempt to improve processing. 
However, this peptide was unable to induce CTL in viva. This result made us think 
that the lack of activity of KQI-KK-RIQ and of KQI-RIQ might perhaps be related 
to poor internalization of these constructs rather than to inefficient processing. 
Surface Exposure of Epitopes 
Since internalization of peptides inside the cells might be related to the topography 
of peptides, we thought of mapping the surface of our constructs with anti-RIQ and 
anti-KQI antibodies. Table 1 shows that the KQI moiety is well “surface exposed” 
only in RIQ-KQI, which is the sole active peptide construct. Since the KQI moiety 
but not RIQ is surface xposed in RIQ-KQI, it would seem logical that if internalization 
of RIQ-KQI inside the cell takes place, this should happen via KQI. 
Efect of Peptide Internalization on CTL Induction 
To study the effect of peptide internalization in the cell on CTL induction in vivo, 
we “forced” internalization of our constructs by hypertonic shock (20, 24). The cells 
thus obtained were used for immunization experiments. Table 2 shows that by contrast 
with immunization with free peptides, where only RIQ-KQI is active, immunization 
with peptide-containing cells (RIQ-KQI, KQI-RIQ, and KQI-KK-RIQ) are all active. 
This proves that peptide internalization render KQI-RIQ, and KQI-KK-RIQ active. 
It is interesting to note that KQI-KK-RIQ is as active as RIQ-KQI but more active 
than KQI-RIQ, this might be related to improved processing due to the added lysines. 
Moreover, because CTL activity was not induced by RIQ alone in either of the two 
groups of immunized mice, it would seem likely that in addition to a potential role 
of KQI in the internalization of RIQ-KQI, help from KQI might be required for CTL 
induction. However, KQI seems to be more effective when covalently linked to RIQ. 
These observations are in agreement with the results reported by Schild for a lipopep- 
tide, where the lipophilic moiety seems to play a role in the internalization (14) and 
has TD, character in another type of construct (18). For similar reasons, it would 
seem that shorter peptides (15-17) able to induce CTL in vivo might contain both 
properties (internalization ability and TDi, character) as the lipophilic moiety or the 
KQI of the above constructs. 
We believe that our results have important implications in vaccination and in the 
treatment of chronic infections, i.e., AIDS and hepatitis B and C. Thus, if the major 
TD, and TD,, determinants (of the corresponding viral antigens) recognized by class 
I and class II MHC molecules of most individuals were known (a research field which 
is quickly developing) constructs like the ones described above could be engineered 
to protect against natural infection and to treat chronically infected individuals. 
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